These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 7941803)

  • 1. [Effect of oral contraceptives on the proliferative activity of breast cancer].
    Schönborn I; Minguillon C; Möhner M
    Zentralbl Gynakol; 1994; 116(7):385-9. PubMed ID: 7941803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Does previous exposure to oral contraceptives modify survival in breast cancer?].
    Schönborn I; Ebeling K; Nischan P
    Geburtshilfe Frauenheilkd; 1994 Oct; 54(10):559-63. PubMed ID: 8001752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
    Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
    Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Researchers can now investigate long-term effects of OCs on cancer.
    Rubin GL; Peterson HB
    Contracept Technol Update; 1985 Jan; 6(1):7-12. PubMed ID: 12279918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral contraceptives and breast cancer.
    Johnson KH; Millard PS
    J Fam Pract; 1996 Oct; 43(4):340-1. PubMed ID: 8874363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Contraception without risk of breast disease: epidemiologic and physiopathologic arguments].
    Le Coutour X
    NPN Med; 1985 Apr; 5(88):471-6. PubMed ID: 12315304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women.
    Gammon MD; Hibshoosh H; Terry MB; Bose S; Schoenberg JB; Brinton LA; Bernstein JL; Thompson WD
    Cancer Epidemiol Biomarkers Prev; 1999 May; 8(5):413-9. PubMed ID: 10350436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of serious illness among oral contraceptive users: evidence from the RCGP's oral contraceptive study.
    Hannaford PC; Kay CR
    Br J Gen Pract; 1998 Oct; 48(435):1657-62. PubMed ID: 10071398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunohistochemical study of the proliferation of breast cancer cells based on the expression of proliferating cell nuclear antigen (PCNA)].
    Uporov AV; Tsyrlina EV; Pozharisskiĭ KM
    Vopr Onkol; 1998; 44(1):49-53. PubMed ID: 9578731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell proliferative activity.
    Donato MF; Arosio E; Del Ninno E; Ronchi G; Lampertico P; Morabito A; Balestrieri MR; Colombo M
    Hepatology; 2001 Sep; 34(3):523-8. PubMed ID: 11526538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks of oral contraceptive use in women over 35.
    Stenchever MA
    J Reprod Med; 1993 Dec; 38(12 Suppl):1030-5. PubMed ID: 8120860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing.
    Jernström H; Loman N; Johannsson OT; Borg A; Olsson H
    Eur J Cancer; 2005 Oct; 41(15):2312-20. PubMed ID: 16118051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparative studies on the biological significance of the marker for proliferation Ki-67-Antigen and PCNA in primary ovarian carcinoma].
    Reitmaier M; Rudlowski C; Biesterfeld S; Rath W; Schröder W
    Zentralbl Gynakol; 2000; 122(7):361-7. PubMed ID: 10951706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer.
    Strom BL; Berlin JA; Weber AL; Norman SA; Bernstein L; Burkman RT; Daling JR; Deapen D; Folger SG; Malone KE; Marchbanks PA; Simon MS; Ursin G; Weiss LK; Spirtas R
    Contraception; 2004 May; 69(5):353-60. PubMed ID: 15105056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGF-R and PCNA expression in ovarian carcinomas--correlation with classic prognostic factors.
    Minguillon C; Schönborn I; Reles A; Bartel U; Lichtenegger W
    Gen Diagn Pathol; 1996 Mar; 141(3-4):197-201. PubMed ID: 8705783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of proliferating cell nuclear antigen (PCNA) in infiltrating ductal carcinoma breast.
    Aziz SA; Pervez S; Khan SM; Kayani N; Nasir MI
    J Coll Physicians Surg Pak; 2005 Apr; 15(4):225-9. PubMed ID: 15857596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The present state of research on the relationship of oral contraceptives to breast cancer].
    Pike MC
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):329-38. PubMed ID: 12280203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heat shock proteins and cell proliferation in human breast cancer biopsy samples.
    Vargas-Roig LM; Fanelli MA; López LA; Gago FE; Tello O; Aznar JC; Ciocca DR
    Cancer Detect Prev; 1997; 21(5):441-51. PubMed ID: 9307847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer metastatic phenotype as predicted by histologic tumor markers.
    Heimann R; Ferguson D; Recant WM; Hellman S
    Cancer J Sci Am; 1997; 3(4):224-9. PubMed ID: 9263628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptosis, PCNA and p53 in hepatocellular carcinoma.
    Paiva C; Oshima CT; Lanzoni VP; Forones NM
    Hepatogastroenterology; 2002; 49(46):1058-61. PubMed ID: 12143201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.